liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Changes in European legislation make it timely to introduce a transparent market surveillance system for cosmetics
Research and Development, ACO HUD Nordic AB, Upplands Väsby, Sweden, ACO Hud Nordic AB, Box 622, SE-194 26 Upplands Väsby, Sweden.
Stockholm Consumer Cooperative Society, Stockholm, Sweden.
Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för klinisk och experimentell medicin, Dermatologi och venerologi. Östergötlands Läns Landsting, Medicincentrum, Hudkliniken i Östergötland.
2007 (engelsk)Inngår i: Acta Dermato-Venereologica, ISSN 0001-5555, E-ISSN 1651-2057, Vol. 87, nr 6, s. 485-492Artikkel i tidsskrift (Annet (populærvitenskap, debatt, mm)) Published
Abstract [en]

Marketing of cosmetics often makes strong claims linked to active ingredients. This is especially so for anti-ageing products, where the presentation and content of "active" ingredients may create new difficulties in their classification as cosmetics or medicinal products. A recent change in European legislation classifies a product as medicinal by virtue of its "function", in addition to the previous definition of "presentation" (i.e. marketing linked to diseases). Thus, formulations that also restore, correct or modify physiological functions by exerting a pharmacological, immunological or metabolic action should henceforth be covered by the Medicinal Products Directive. A cosmetic product must be suitable for its purpose and should not lead to adverse reactions that are disproportional in relation to its intended effect. However, the forthcoming ban on animal testing of cosmetic ingredients and the new European regulation, REACH (Registration, Evaluation and Authorisation of Chemicals), which aims to ensure a high level of chemical safety to protect human health and the environment, will probably have limited impact on the safety assessment of cosmetics. In order to enable consumers to make informed purchasing decisions, greater transparency in the process of assessing the performance of cosmetics is needed. Introduction of a more transparent system, enabling consumers and professionals to examine the scientific evidence for the claimed effect and the safety assessment of cosmetics, is therefore timely. Lack of transparency increases the risk of consumers wasting money on cosmetics that do not deliver the desired effects. This may jeopardize public trust in the cosmetic industry.

sted, utgiver, år, opplag, sider
Society for the Publication of Acta Dermato - Venereologica , 2007. Vol. 87, nr 6, s. 485-492
Emneord [en]
Claim substantiation, Efficacy, Misleading, Pharmaceuticals, Safety
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-47544DOI: 10.2340/00015555-0311ISI: 000251213300003PubMedID: 17989885Scopus ID: 2-s2.0-38849174557OAI: oai:DiVA.org:liu-47544DiVA, id: diva2:268440
Tilgjengelig fra: 2009-10-11 Laget: 2009-10-11 Sist oppdatert: 2017-12-13bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedScopus

Personposter BETA

Serup, Jörgen

Søk i DiVA

Av forfatter/redaktør
Serup, Jörgen
Av organisasjonen
I samme tidsskrift
Acta Dermato-Venereologica

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 123 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf